Trend
DailyUptrend (starting)
4 hourLeaning Bearish
1 hourSymmetric Triangle
15 minLeaning Bullish
5 minStrong Bearish
Daily trend turns down below $17.70
Key levels
Resistance$22.05
Resistance$20.70
Support$18.84
Support$17.52
Latest news & SEC filings
DealVor Bio amends RemeGen license to add autoimmune candidate RC298 for about $56M upfront
SEC FilingVor Biopharma Inc. filed a report on a major company event (Form 8-K)
All VOR news →Vor Biopharma develops treatments for autoimmune conditions. Its main candidate, telitacicept, blocks two signaling molecules involved in B cell activity and is in late-stage worldwide testing for myasthenia gravis and Sjögren's disease. The company holds rights to sell and develop this drug everywhere except mainland China, Hong Kong, Macau and Taiwan, where RemeGen keeps those rights. Earlier work on engineered cell and CAR-T therapies for blood cancers has been wound down.
Based on the company's 10-K filed Mar 30, 2026.
Nasdaq · Healthcare
SEPT Low Target
$15.00
SEPT Mid Target
$29.00
SEPT High Target
$50.00
Analyst Consensus
$29.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for VOR.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$29.00
17
Moat Score
NONE
2/9
Piotroski Score
-4.8
Altman Z-Score
Insider Signal
SELLING
0 buys / 15 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Sokolove Jeremy Brett | officer | Sale | 1,917 | $37K | Nov 2, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 10% owner | Buy | 500 | $6K | Oct 2, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-107.17%
FCF Growth YoY
-43.8%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for VOR, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 12:53:40 | $20.10 | 1,000 | $$20K | BUY |
| 21:00:19 | $20.09 | 1,113 | $$22K | BUY |
| 21:00:18 | $20.09 | 1,132 | $$23K | BUY |
| 21:00:17 | $20.09 | 8,781 | $$176K | BUY |
| 20:59:54 | $20.11 | 1,200 | $$24K | BUY |
5 dark pool trades shown · $$266K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for VOR. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
SEPT Brain on $VOR -- Bullish VOR at $18.39. Day range $17.90-$19.13. Last candle: doji (36% buying). Price testing zone top $19.11. Demand zone (84% institutional buying). Break above = buyers still...
Join 3,500+ traders discussing VOR in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
SEPT's Trading AI has generated a free, downloadable PDF research report for Vor Biopharma Inc. (VOR) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Vor Biopharma Inc. (VOR) is at $19.29, down 3.98% (-$0.80) at the Nov 12, 2026 close.
Latest VOR news — Nov 12, 2026: Vor Bio amends RemeGen license to add autoimmune candidate RC298 for about $56M upfront · Nov 12, 2026: Vor Biopharma Inc. filed a report on a major company event (Form 8-K)
The average analyst price target for VOR is $29.00, ranging from $15 to $50, based on 4 analysts. Latest: Wedbush maintains on Aug 12, 2026.
Analyst ratings for VOR: 1 Buy, 3 Hold, 0 Sell — consensus Hold.
VOR last reported on Aug 11, 2026: EPS -$1.16 vs -$0.69 expected — a miss of 68.1%.
VOR trades at a P/E of 0.1 vs a Healthcare average of 18.4.
Support: $18.84, $17.52, $14.85. Resistance: $20.70, $22.05, $24.45.
Insider activity: SELLING, 0 buys and 15 sells in the last 90 days.
Nov 12, 2026: Vor Bio amends RemeGen license to add autoimmune candidate RC298 for about $56M upfront · Nov 12, 2026: Vor Biopharma Inc. filed a report on a major company event (Form 8-K)